Strong result with guidance ahead. Key risk to the stock is decelerating growth off a high base and increased pricing headwinds dragging on the multiple.
I agree but I'm also wary about LLY being a name poeple are positioning in for the oral Wegovy/Mounjaro approval spike. I get the feeling it will be sold hard with that revenue growth slowdown in the back of HFs minds. Its potentially a crowded trade (and this coming from a holder whos constantly reassessing position weight)
I agree but I'm also wary about LLY being a name poeple are positioning in for the oral Wegovy/Mounjaro approval spike. I get the feeling it will be sold hard with that revenue growth slowdown in the back of HFs minds. Its potentially a crowded trade (and this coming from a holder whos constantly reassessing position weight)